Clearmind Medicine (NASDAQ:CMND) is a clinical-stage biotechnology company focused on the development and commercialization of novel psychedelic medicines for the treatment of mental health disorders. Founded in 2018 and headquartered in Vancouver, Canada, the company aims to harness the therapeutic potential of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and other psychoactive compounds to address conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD) and substance use disorders. Clearmind’s mission centers on advancing a new generation of rapid-acting, non-hallucinogenic or short-duration treatments that can deliver meaningful relief to patients who have not responded to conventional therapies.
Clearmind’s lead development program, CMND-100, investigates the safety, tolerability and preliminary efficacy of intranasal 5-MeO-DMT in adults with treatment-resistant depression. In addition to its flagship candidate, the company’s pipeline includes discovery-stage programs focused on proprietary formulations of 5-MeO-DMT and other tryptamine derivatives designed to optimize pharmacokinetic profiles and minimize hallucinogenic experiences. These programs are supported by in-house research capabilities and collaborations with academic institutions and contract research organizations to advance preclinical and clinical studies.
The company serves patients and research partners across North America and Europe, leveraging a network of clinical trial sites and strategic collaborations. Clearmind holds a portfolio of intellectual property covering composition of matter, delivery technologies and therapeutic uses of 5-MeO-DMT. Through partnerships with leading neuroscience centers, the company seeks to expand its preclinical research into neural mechanisms of action and biomarkers of treatment response, while exploring opportunities for global expansion as regulatory frameworks for psychedelic therapies evolve.
Under the leadership of CEO Ian T. Smith, Clearmind has pursued an integrated strategy that combines proprietary chemistry, rigorous clinical development and a commitment to safety and patient experience. The company’s management team brings deep expertise in pharmaceutical development, neuroscience and regulatory affairs, positioning Clearmind to advance its clinical-stage assets toward potential commercialization. Looking ahead, Clearmind aims to further de-risk its late-stage programs by generating robust clinical data and engaging with regulators to establish a clear path toward approval and market access for its innovative psychedelic therapies.
